Form 4: Enliven Therapeutics Director Richard A. Heyman Sells Shares Under 10b5-1 Trading Plan

Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics (ELVN) at a weighted average price of $27.6719, according to a Form 4 filing.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc. (ELVN), sold 1,270 shares of common stock on October 15, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 17, 2023.
• The weighted average sale price was $27.6719, with individual transactions ranging from $27.1521 to $27.9631.
• Following the transaction, Heyman directly owns 124,490 shares.
• He also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 27,918 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares.

Industry Context

Sales by company insiders are common and are often pre-planned through 10b5-1 trading plans to avoid accusations of trading on non-public information. The market typically views such sales in the context of the overall trading plan and the insider's remaining holdings.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates this concern.

Key Dates